Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. META
4. DPZ
5. IBM
6. CNC
7. KFY
8. SPY
9. MU
10. ENRD

Go back to Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy
ULTRAGENYX PHARM (NASDAQ: RARE) Delayed: 29.03 --0 (-0%)
Previous Close $29.03    52 Week High $117.12 
Open $29.03    52 Week Low $46.52 
Day High $29.03    P/E N/A 
Day Low $29.03    EPS $-1.97 
Volume 448       

(NASDAQ: SLDB) Delayed: 8.30 --0 (-0%)
Previous Close $8.30    52 Week High $ 
Open $8.30    52 Week Low $ 
Day High $8.30    P/E N/A 
Day Low $8.30    EPS $ 
Volume 1,480